• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

A small but significant new study showed low doses of Ozempic helped people to drink less. Scientists are starting to ...

Eli Lilly should easily beat the market again in 2025, as it did in 2024. Summit Therapeutics awaits a potentially huge ...

Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as well as their implications for other applications like kidney disease and ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Key Takeaways New data show that GLP1-RA meds like semaglutide can help slow the progression of chronic kidney diseaseThe ...